Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group

scientific article

Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1200/JCO.2005.05.1359
P8608Fatcat IDrelease_tiikkbxhn5covo4hklhe6kw2bm
P698PubMed publication ID16809726

P2093author name stringAnnie Robert
Jan P van Meerbeeck
Richard Sylvester
Catherine Legrand
Martine Van Glabbeke
Julie Francart
P433issue19
P407language of work or nameEnglishQ1860
P921main subjectphase II clinical trialQ42824440
P304page(s)3007-3012
P577publication date2006-07-01
P1433published inJournal of Clinical OncologyQ400292
P1476titleProgression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group
P478volume24